These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9403896)

  • 21. D2 dopamine receptor binding in the basal ganglia of antipsychotic-free schizophrenic patients. An 123I-IBZM single photon emission computerised tomography study.
    Pilowsky LS; Costa DC; Ell PJ; Verhoeff NP; Murray RM; Kerwin RW
    Br J Psychiatry; 1994 Jan; 164(1):16-26. PubMed ID: 8137105
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gender differences in D2 dopamine receptor binding in drug-naive patients with schizophrenia: an [123I]iodobenzamide single photon emission computed tomography study.
    Schröder J; Bubeck B; Silvestri S; Demisch S; Sauer H
    Psychiatry Res; 1997 Sep; 75(2):115-23. PubMed ID: 9351493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [123I]IBZM SPECT in patients treated with typical and atypical neuroleptics: relationship to drug plasma levels and extrapyramidal side effects.
    Schlösser R; Schlegel S; Hiemke C; Nickel O; Bockisch A; Rao ML; Hahn K
    Psychiatry Res; 1997 Sep; 75(2):103-14. PubMed ID: 9351492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson's disease and controls.
    Eisensehr I; Linke R; Noachtar S; Schwarz J; Gildehaus FJ; Tatsch K
    Brain; 2000 Jun; 123 ( Pt 6)():1155-60. PubMed ID: 10825354
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dopamine D2 receptors in depression measured with single photon emission computed tomography.
    D'haenen HA; Bossuyt A
    Biol Psychiatry; 1994 Jan; 35(2):128-32. PubMed ID: 8167208
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects.
    Laruelle M; Abi-Dargham A; van Dyck CH; Gil R; D'Souza CD; Erdos J; McCance E; Rosenblatt W; Fingado C; Zoghbi SS; Baldwin RM; Seibyl JP; Krystal JH; Charney DS; Innis RB
    Proc Natl Acad Sci U S A; 1996 Aug; 93(17):9235-40. PubMed ID: 8799184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prolactin plasma levels and D2-dopamine receptor occupancy measured with IBZM-SPECT.
    Schlegel S; Schlösser R; Hiemke C; Nickel O; Bockisch A; Hahn K
    Psychopharmacology (Berl); 1996 Apr; 124(3):285-7. PubMed ID: 8740053
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetically determined measures of striatal D2 signaling predict prefrontal activity during working memory performance.
    Bertolino A; Taurisano P; Pisciotta NM; Blasi G; Fazio L; Romano R; Gelao B; Lo Bianco L; Lozupone M; Di Giorgio A; Caforio G; Sambataro F; Niccoli-Asabella A; Papp A; Ursini G; Sinibaldi L; Popolizio T; Sadee W; Rubini G
    PLoS One; 2010 Feb; 5(2):e9348. PubMed ID: 20179754
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alterations of striatal dopamine D2 receptors contribute to deteriorated response to L-dopa in Parkinson's disease: a [123I]-IBZM SPET study.
    Pizzolato G; Chierichetti F; Rossato A; Cagnin A; Fabbri M; Dam M; Ferlin G; Battistin L
    J Neural Transm Suppl; 1995; 45():113-22. PubMed ID: 8748616
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Striatal dopamine release in reading and writing measured with [123I]iodobenzamide and single photon emission computed tomography in right handed human subjects.
    Schommartz B; Larisch R; Vosberg H; Müller-Gärtner HM
    Neurosci Lett; 2000 Sep; 292(1):37-40. PubMed ID: 10996444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiple system atrophy and progressive supranuclear palsy. Diminished striatal D2 dopamine receptor activity demonstrated by 123I-IBZM single photon emission computed tomography.
    van Royen E; Verhoeff NF; Speelman JD; Wolters EC; Kuiper MA; Janssen AG
    Arch Neurol; 1993 May; 50(5):513-6. PubMed ID: 8489409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 123I-IBZM SPECT: reconstruction methodology and results in parkinsonism and dystonia.
    Berding G; Gratz KF; Kolbe H; Meyer GJ; Dengler R; Knoop BO; Hundeshagen H
    Nuklearmedizin; 1994 Oct; 33(5):194-9. PubMed ID: 7997377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lateralized differences in iodine-123-IBZM uptake in the basal ganglia in asymmetric Parkinson's disease.
    Knable MB; Jones DW; Coppola R; Hyde TM; Lee KS; Gorey J; Weinberger DR
    J Nucl Med; 1995 Jul; 36(7):1216-25. PubMed ID: 7790947
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic value of asymmetric striatal D2 receptor upregulation in Parkinson's disease: an [123I]IBZM and [123I]FP-CIT SPECT study.
    Verstappen CC; Bloem BR; Haaxma CA; Oyen WJ; Horstink MW
    Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):502-7. PubMed ID: 17053905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo measurement of haloperidol affinity to dopamine D2/D3 receptors by [123I]IBZM and single photon emission computed tomography.
    Videbaek C; Toska K; Friberg L; Holm S; Angelo HR; Knudsen GM
    J Cereb Blood Flow Metab; 2001 Jan; 21(1):92-7. PubMed ID: 11149673
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Individual variation in D2 dopamine receptor occupancy in clozapine-treated patients.
    Pickar D; Su TP; Weinberger DR; Coppola R; Malhotra AK; Knable MB; Lee KS; Gorey J; Bartko JJ; Breier A; Hsiao J
    Am J Psychiatry; 1996 Dec; 153(12):1571-8. PubMed ID: 8942453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of motor activity on striatal dopamine release: A study using iodobenzamide and SPECT.
    Larisch R; Schommartz B; Vosberg H; Müller-Gärtner HW
    Neuroimage; 1999 Sep; 10(3 Pt 1):261-8. PubMed ID: 10458941
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantification of IBZM dopamine receptor SPET in de novo Parkinson patients before and during therapy.
    Hertel A; Weppner M; Baas H; Schreiner M; Maul FD; Baum RP; Fischer PA; Hör G
    Nucl Med Commun; 1997 Sep; 18(9):811-22. PubMed ID: 9352546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes.
    Hierholzer J; Cordes M; Venz S; Schelosky L; Harisch C; Richter W; Keske U; Hosten N; Mäurer J; Poewe W; Felix R
    J Nucl Med; 1998 Jun; 39(6):954-60. PubMed ID: 9627325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amphetamine-stimulated dopamine release competes in vivo for [123I]IBZM binding to the D2 receptor in nonhuman primates.
    Innis RB; Malison RT; al-Tikriti M; Hoffer PB; Sybirska EH; Seibyl JP; Zoghbi SS; Baldwin RM; Laruelle M; Smith EO
    Synapse; 1992 Mar; 10(3):177-84. PubMed ID: 1532675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.